Judith M Kramer

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Impediments to clinical research in the United States
    J M Kramer
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Clin Pharmacol Ther 91:535-41. 2012
  2. ncbi request reprint Managing the risks of therapeutic products: proceedings of a workshop
    Judith M Kramer
    Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC 27715, USA
    Pharmacoepidemiol Drug Saf 14:619-28. 2005
  3. ncbi request reprint National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance
    Judith M Kramer
    Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 152:454.e1-8. 2006
  4. doi request reprint Long-term clinical outcomes following coronary stenting
    Kevin J Anstrom
    Department of Biostatistics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:1647-55. 2008
  5. ncbi request reprint Multifaceted intervention to promote beta-blocker use in heart failure
    Nancy M Allen LaPointe
    Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 151:992-8. 2006
  6. doi request reprint Postmarket evaluation of breakthrough technologies
    Sunil V Rao
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 156:201-8. 2008
  7. ncbi request reprint Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
    L Kristin Newby
    Centers for Education and Research on Therapeutics, Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circulation 113:203-12. 2006
  8. ncbi request reprint Part II: Sealing holes in the safety net
    Eric D Peterson
    Centers for Education and Research on Therapeutics CERTs Coordinating Center, Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 147:985-90. 2004
  9. ncbi request reprint Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases
    Lesley H Curtis
    Duke Clinical Research Institute, and Departments of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
    Med Care 45:S103-7. 2007
  10. doi request reprint The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment
    Robert M Califf
    Duke Translational Medicine Institute, Durham, NC 27715, USA
    Pharmacoepidemiol Drug Saf 17:782-6. 2008

Detail Information

Publications35

  1. doi request reprint Impediments to clinical research in the United States
    J M Kramer
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Clin Pharmacol Ther 91:535-41. 2012
    ....
  2. ncbi request reprint Managing the risks of therapeutic products: proceedings of a workshop
    Judith M Kramer
    Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC 27715, USA
    Pharmacoepidemiol Drug Saf 14:619-28. 2005
    ..Patients deserve no less as we strive to protect their safety...
  3. ncbi request reprint National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance
    Judith M Kramer
    Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 152:454.e1-8. 2006
    ..We sought to examine long-term beta-blocker adherence over the first year after myocardial infarction in patients with commercial health insurance and prescription drug benefits...
  4. doi request reprint Long-term clinical outcomes following coronary stenting
    Kevin J Anstrom
    Department of Biostatistics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:1647-55. 2008
    ..The objective of this study was to compare the long-term clinical outcomes of patients receiving DES vs BMS in a clinical practice setting...
  5. ncbi request reprint Multifaceted intervention to promote beta-blocker use in heart failure
    Nancy M Allen LaPointe
    Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 151:992-8. 2006
    ..Despite a survival benefit and guideline recommendation for beta-blockers in left ventricular systolic dysfunction, beta-blockers are underused in clinical practice...
  6. doi request reprint Postmarket evaluation of breakthrough technologies
    Sunil V Rao
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 156:201-8. 2008
    ....
  7. ncbi request reprint Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
    L Kristin Newby
    Centers for Education and Research on Therapeutics, Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circulation 113:203-12. 2006
    ..Studies have examined the use of evidence-based therapies for coronary artery disease (CAD) in the short term and at hospital discharge, but few have evaluated long-term use...
  8. ncbi request reprint Part II: Sealing holes in the safety net
    Eric D Peterson
    Centers for Education and Research on Therapeutics CERTs Coordinating Center, Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 147:985-90. 2004
  9. ncbi request reprint Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases
    Lesley H Curtis
    Duke Clinical Research Institute, and Departments of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
    Med Care 45:S103-7. 2007
    ..Finally, we offer detailed guidance about how to implement the estimators in comparative effectiveness analyses...
  10. doi request reprint The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment
    Robert M Califf
    Duke Translational Medicine Institute, Durham, NC 27715, USA
    Pharmacoepidemiol Drug Saf 17:782-6. 2008
  11. ncbi request reprint Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation
    L Kristin Newby
    Duke Clinical Research Institute and the Duke Centers for Education and Research on Therapeutics CERTs, Durham, NC 27715 7969, USA
    J Thromb Thrombolysis 16:119-28. 2003
    ..While aspirin's secondary prevention benefit is clear, prior reports indicate that 19-83% of eligible patients may not use aspirin chronically...
  12. ncbi request reprint Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    Eric L Eisenstein
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 297:159-68. 2007
    ..Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis...
  13. doi request reprint Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010
    Robert M Califf
    Duke Translational Medicine Institute, 200 Trent Dr, 1117 Davison Bldg, Durham, NC 27710, USA
    JAMA 307:1838-47. 2012
    ..Strengthened reporting requirements for studies registered with ClinicalTrials.gov enable a comprehensive evaluation of the national trials portfolio...
  14. doi request reprint Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial
    Sara Bristol Calvert
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 163:657-65.e1. 2012
    ..Nonadherence to cardiovascular medications is a significant public health problem. This randomized study evaluated the effect on medication adherence of linking hospital and community pharmacists...
  15. doi request reprint Comparative effectiveness of beta-blockers in elderly patients with heart failure
    Judith M Kramer
    Department of Medicine, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:2422-8; discussion 2428-32. 2008
    ..We compared the effectiveness of EBBBs vs non-EBBBs on survival...
  16. pmc Early and long-term outcomes of heart failure in elderly persons, 2001-2005
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:2481-8. 2008
    ..The treatment of chronic heart failure has improved during the past 2 decades, but little is known about whether the improvements are reflected in trends in early and long-term mortality and hospital readmission...
  17. ncbi request reprint Frequency of high-risk use of QT-prolonging medications
    Nancy M Allen LaPointe
    Duke Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Pharmacoepidemiol Drug Saf 15:361-8. 2006
    ..Concurrent use of more than one QT-prolonging drug or a QT-prolonging drug with a drug that alters its pharmacokinetic profile is an important risk factor for adverse outcomes...
  18. ncbi request reprint Underuse of aspirin in a referral population with documented coronary artery disease
    Robert M Califf
    Centers for Education and Research on Therapeutics CERTs, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 89:653-61. 2002
    ..The health care system currently lacks effective methods to ensure that patients who have CAD have adequate follow-up concerning aspirin use...
  19. ncbi request reprint Patient-reported frequency of taking aspirin in a population with coronary artery disease
    Nancy M Allen LaPointe
    Duke CERTs Centers for Education and Research on Therapeutics at the Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 89:1042-6. 2002
    ..Although the rate of aspirin use in this population was higher than previously reported, an estimated 6% of eligible patients were not receiving antiplatelet therapy...
  20. ncbi request reprint Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure
    Monica R Shah
    Duke Clinical Research Institute, P O Box 17969, Durham, NC 27715, USA
    Eur J Heart Fail 4:297-304. 2002
    ..Changes in hemodynamic measures often serve as surrogate end points in efficacy trials for advanced heart failure, although there are few objective data to support this practice...
  21. ncbi request reprint Practitioner acceptance of the dofetilide risk-management program
    Nancy M Allen LaPointe
    Duke Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Pharmacotherapy 22:1041-6. 2002
    ..To assess the opinions and knowledge retention of practitioners after participation in the dofetilide risk-management program...
  22. ncbi request reprint Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000
    Sana M Al-Khatib
    Duke Center for Education and Research on Therapeutics CERTs at the Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 91:91-4. 2003
  23. ncbi request reprint What clinicians should know about the QT interval
    Sana M Al-Khatib
    Duke Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 289:2120-7. 2003
    ..Of the several factors implicated in causing QT interval prolongation and torsades de pointes, errors in the use of medications that may prolong this interval deserve special attention...
  24. ncbi request reprint Knowledge deficits related to the QT interval could affect patient safety
    Nancy M Allen LaPointe
    Duke CERTs Centers for Education and Research on Therapeutics at the Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Ann Noninvasive Electrocardiol 8:157-60. 2003
    ..S. Food and Drug Administration. This led us to assess the health care practitioners' knowledge of the QT interval and medications that may prolong it...
  25. ncbi request reprint New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance
    Nancy M Allen LaPointe
    Duke Center for Education and Research on Therapeutics, Duke Clinical Research Institute, P O Box 17969, Durham, NC 27715, USA
    Pharmacotherapy 23:1316-21. 2003
    ....
  26. doi request reprint Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease
    Nancy M Allen LaPointe
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 103:1518-24. 2009
    ..We were unable to demonstrate a statistically significant association between persistent ACEI/ARB use and survival...
  27. pmc A survey of health care practitioners' knowledge of the QT interval
    Sana M Al-Khatib
    Duke Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, NC 27715, USA
    J Gen Intern Med 20:392-6. 2005
    ..To assess health care practitioners' ability to correctly measure the QT interval, and to identify factors and medications that may increase the risk of QT-interval prolongation and torsades de pointes...
  28. ncbi request reprint Spending on postapproval drug safety
    David B Ridley
    Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:429-36. 2006
    ..This study offers information for the debate on proposed changes to safety surveillance...
  29. doi request reprint Scientific evidence underlying the ACC/AHA clinical practice guidelines
    Pierluigi Tricoci
    Division of Cardiology and Duke Clinical Research Institute, Duke University, Durham, North Carolina 27705, USA
    JAMA 301:831-41. 2009
    ....
  30. ncbi request reprint International variation in the use of evidence-based medicines for acute coronary syndromes
    Judith M Kramer
    Duke University Medical Center, Duke Center for Education and Research on Therapeutics, and Duke Clinical Research Institute, NC, Durham, USA
    Eur Heart J 24:2133-41. 2003
    ..We sought to evaluate international patterns of use and factors influencing use of evidence-based medications early after ACS...
  31. ncbi request reprint Evaluation of the dofetilide risk-management program
    Nancy M Allen LaPointe
    Duke Center for Education and Research on Therapeutics and the Division of Cardiology, Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 146:894-901. 2003
    ..We investigated whether this program improved adherence to dosing and monitoring recommendations for dofetilide as compared with sotalol...
  32. ncbi request reprint Part I: Identifying holes in the safety net
    J Conor O'Shea
    Duke Center for Education and Research on Therapeutics CERTs Research Center, Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 147:977-84. 2004
  33. ncbi request reprint Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women
    Warren J Cantor
    St Michael s Hospital, Toronto, Ontario, Canada
    Am Heart J 144:297-302. 2002
    ..Differences in target vessel size may partially account for these differences. We set out to explore the effects of sex, body surface area (BSA), and target coronary vessel size on clinical outcomes after angioplasty...
  34. doi request reprint A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction
    David H Smith
    Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227, USA
    Arch Intern Med 168:477-83; discussion 483; quiz 447. 2008
    ..We sought to test the hypothesis that a simple, direct-to-patient intervention can improve adherence to beta-blocker therapy following MI...
  35. ncbi request reprint Case reports of heart failure after therapy with a tumor necrosis factor antagonist
    Hyon J Kwon
    Division of Epidemiology, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Rockville, Maryland 20852, USA
    Ann Intern Med 138:807-11. 2003
    ..Etanercept and infliximab are U.S. Food and Drug Administration-approved tumor necrosis factor (TNF) antagonists...